Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
Status:
Completed
Trial end date:
2019-04-14
Target enrollment:
Participant gender:
Summary
Main Study (CACZ885M2301): The purpose of the pivotal phase of this trial was to test the
hypothesis that canakinumab treatment of patients with myocardial infarction (MI) at least
one month prior to study entry and elevated hsCRP could prevent recurrent cardiovascular
events.
The purpose of the extension phase of the main study is to collect additional long-term
safety data on continued exposure to canakinumab in patients who participated in the pivotal
phase.
Sub-study 1 (CACZ885M2301S1): The purpose of this sub-study was to evaluate the effect of
quarterly subcutaneous canakinumab treatment for 24 months comparted with placebo on the
carotid plaque burden measured by integrated vascular MRI in patients enrolled in the
CACZ885M2301 study (CANTOS).
Sub-study 2 (CACZ885M2301S2): The purpose of this CANTOS sub-study was to determine whether,
in patients with type 2 diabetes participating in the CANTOS main study, canakinumab compared
to placebo, on top of standard of care could increase insulin secretion and insulin
sensitivity.